Circulating dipeptidyl peptidase 3 and bio-adrenomedullin levels are associated with impaired outcomes in critically ill COVID-19 patients: a prospective international multicentre study.

Dirk van LierBenjamin DeniauKarine SantosOliver HartmannEmmanuel DudoignonFrançois DepretBenoit PlaudPierre-Francois LaterreAlexandre MebazaaPeter Pickkers

Published in: ERJ open research (2023)

cDPP3 and bio-ADM responses were associated with short-term mortality and AKI in critically ill COVID-19 patients, respectively. These findings suggest that treatment with specific antibodies modulating cDPP3 or bio-ADM-related pathways may improve outcome of COVID-19.

Keyphrases

sars cov
coronavirus disease
cardiovascular events
signaling pathway
risk factors
cardiovascular disease
adipose tissue
skeletal muscle
replacement therapy